Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Lestaurtinib pancreatic ductal adenocarcinoma not applicable detail...
KRAS mutant PD-0325901 + Gedatolisib pancreatic ductal adenocarcinoma sensitive detail...
CDH1 over exp Erlotinib + Selumetinib pancreatic ductal adenocarcinoma sensitive detail...
Unknown unknown PI-3065 pancreatic ductal adenocarcinoma not applicable detail...
Unknown unknown MN58b + Gemcitabine pancreatic ductal adenocarcinoma not applicable detail...
Unknown unknown MN58b + Fluorouracil pancreatic ductal adenocarcinoma not applicable detail...
Unknown unknown MN58b + Oxaliplatin pancreatic ductal adenocarcinoma not applicable detail...
Unknown unknown Gemcitabine + Masitinib pancreatic ductal adenocarcinoma not applicable detail...
Unknown unknown MitoMet-10 pancreatic ductal adenocarcinoma not applicable detail...
Unknown unknown MitoMet-10 + Radiotherapy pancreatic ductal adenocarcinoma not applicable detail...
Unknown unknown JQ1 pancreatic ductal adenocarcinoma not applicable detail...
Unknown unknown Gemcitabine + JQ1 pancreatic ductal adenocarcinoma not applicable detail...
KRAS mutant Dinaciclib + MK2206 pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12D TP53 R175H Sirolimus pancreatic ductal adenocarcinoma conflicting detail...
KRAS mutant AZD8186 + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant AZD8186 + Ulixertinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant SCH772984 + Temsirolimus pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Ridaforolimus + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Everolimus + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Pictilisib + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant AZD8055 + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant OSI-027 + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant SCH772984 + Vistusertib pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant MK2206 + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Navitoclax + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Danusertib + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Ralimetinib + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Panobinostat + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Linsitinib + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Nilotinib + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant PF-04691502 + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Saracatinib + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant BMS-754807 + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Midostaurin + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Dasatinib + SCH772984 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Ipatasertib + Selumetinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Pictilisib + Selumetinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Saracatinib + Selumetinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant Neratinib + Selumetinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12D TP53 R175H Gemcitabine + SRA737 pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12D TP53 R175H SRA737 pancreatic ductal adenocarcinoma sensitive detail...
KRAS mutant BEZ235 + PD-0325901 pancreatic ductal adenocarcinoma predicted - sensitive detail...
EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83* Crizotinib pancreatic ductal adenocarcinoma resistant detail...
EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83* Alectinib pancreatic ductal adenocarcinoma predicted - sensitive detail...
Unknown unknown Reolysin + Gemcitabine pancreatic ductal adenocarcinoma not applicable detail...
Unknown unknown Selumetinib + SHP099 pancreatic ductal adenocarcinoma not applicable detail...
KRAS G12C Selumetinib pancreatic ductal adenocarcinoma decreased response detail...
KRAS G12V Selumetinib pancreatic ductal adenocarcinoma decreased response detail...
KRAS G12C Selumetinib + SHP099 pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12D Selumetinib + SHP099 pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12V Selumetinib + SHP099 pancreatic ductal adenocarcinoma sensitive detail...
KRAS Q61R Selumetinib + SHP099 pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12R Selumetinib + SHP099 pancreatic ductal adenocarcinoma predicted - sensitive detail...
KRAS G12C SHP099 + Trametinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12V SHP099 + Trametinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12C PTPN11 P491Q Selumetinib + SHP099 pancreatic ductal adenocarcinoma resistant detail...
KRAS G12D Selumetinib pancreatic ductal adenocarcinoma decreased response detail...
KRAS Q61R Selumetinib pancreatic ductal adenocarcinoma decreased response detail...
KRAS G12R Selumetinib pancreatic ductal adenocarcinoma decreased response detail...
BRAF N486_P490del Trametinib pancreatic ductal adenocarcinoma predicted - sensitive detail...
KRAS G12V PTPN11 loss Selumetinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12V PTPN11 loss Trametinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12V GS-493 + Selumetinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12V Trametinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12D PTPN11 loss Selumetinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12D PTPN11 loss Trametinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12D GS-493 + Selumetinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12D GS-493 + Trametinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12D SHP099 + Trametinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12D PTPN11 E76A GS-493 + Selumetinib pancreatic ductal adenocarcinoma sensitive detail...
KRAS G12D PTPN11 E76A Selumetinib + SHP099 pancreatic ductal adenocarcinoma resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01647828 Phase Ib/II nab-paclitaxel Gemcitabine Tarextumab A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Completed
NCT02042378 Phase II Rucaparib A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation Completed
NCT02101021 Phase II Nab-paclitaxel + Gemcitabine Momelotinib Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Terminated
NCT02109445 Phase II Nab-paclitaxel + Gemcitabine PF-03084014 Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies Terminated
NCT02241187 Phase I Cetuximab + PEGPH20 Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection Completed
NCT02259114 Phase I Birabresib A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed
NCT02289898 Phase II Demcizumab + Gemcitabine + nab-paclitaxel Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Completed
NCT02362048 Phase II Acalabrutinib Pembrolizumab ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer Active, not recruiting
NCT02501902 Phase I nab-paclitaxel + Palbociclib Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC Completed
NCT02559492 Phase I INCB039110 + INCB024360 INCB039110 + INCB050465 INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting
NCT02583477 Phase Ib/II AZD5069 + MEDI4736 Gemcitabine + MEDI4736 + nab-paclitaxel Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Completed
NCT02600949 Phase I Pembrolizumab Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma Active, not recruiting
NCT02672917 Phase I MVT-5873 Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies Recruiting
NCT02732938 Phase I Gemcitabine + nab-paclitaxel + PF-04136309 Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i) Terminated
NCT02754726 Phase II Cisplatin + Gemcitabine + nab-paclitaxel + Nivolumab + Paricalcitol Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting
NCT02810418 Phase Ib/II LMB-100 LMB-100 + nab-paclitaxel Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Recruiting
NCT02857270 Phase I LY3214996 LY3214996 + nab-paclitaxel + Gemcitabine LY3214996 + Midazolam LY3214996 + Abemaciclib A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Recruiting
NCT02879318 Phase II Nab-paclitaxel + Gemcitabine Durvalumab + Tremelimumab Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma Active, not recruiting
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Recruiting
NCT02942095 Phase I Erlotinib + Ixazomib Phase I Study of Ixazomib and Erlotinib in Solid Tumors Recruiting
NCT02978547 Phase II Metformin The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (Metformin 001) Not yet recruiting
NCT02981342 Phase II Capecitabine Abemaciclib Gemcitabine Abemaciclib + LY3023414 Abemaciclib + Galunisertib A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Active, not recruiting
NCT02993731 Phase III Gemcitabine + nab-paclitaxel + Napabucasin Nab-paclitaxel + Gemcitabine A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P) Active, not recruiting
NCT03038477 Phase II Durvalumab A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection Suspended
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Recruiting
NCT03118349 Phase I MVT-1075 + MVT-5873 Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy Recruiting
NCT03193190 Phase Ib/II Atezolizumab + BKT140 Gemcitabine + Nab-Paclitaxel + mFOLFOX-6 Atezolizumab + PEGPH20 Atezolizumab + Cobimetinib A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting
NCT03264404 Phase II Azacitidine + Pembrolizumab Azacitidine and Pembrolizumab in Pancreatic Cancer Recruiting
NCT03412799 Phase I Gemcitabine + nab-paclitaxel + SBP-101 Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer Recruiting
NCT03432676 Phase II Epacadostat + Pembrolizumab Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD) Withdrawn
NCT03450018 Phase Ib/II Gemcitabine + SLC-0111 A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (SLC-0111-17-01) Not yet recruiting
NCT03496662 Phase Ib/II Nivolumab BMS-813160 + Gemcitabine + nab-paclitaxel Nab-paclitaxel + Gemcitabine BMS-813160 + Gemcitabine + nab-paclitaxel + Nivolumab BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting
NCT03634332 Phase II PEGPH20 + Pembrolizumab Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC Not yet recruiting
NCT03637491 Phase II Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors Recruiting
NCT03681951 Phase Ib/II GSK3145095 GSK3145095 + Pembrolizumab First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors Recruiting
NCT03682289 Phase II AZD6738 + Olaparib Olaparib Phase II Trial of AZD6738 Alone and in Combination With Olaparib Recruiting
NCT03727880 Phase II Defactinib + Pembrolizumab Pembrolizumab Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma Not yet recruiting
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Recruiting